Publicity

Please join BioInvest FREE at The MoneyShow’s TradersEXPO in Las Vegas on April 24-26. In this session, John will explain the methodology he uses to sift through hundreds of biotech companies to find the best-in-class drugs like MDGL for longterm growth.

Please join BioInvest FREE at The MoneyShow live streaming event on October 12 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country. #MYOV #MDGL #PGEN #TCRT

Please join BioInvest FREE at The MoneyShow live streaming event on September 8 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country.

Please join BioInvest FREE at The MoneyShow live streaming event from December 7-9 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country.

At the recent JPMorgan Conference, biotech BioMarin Pharmaceutical (BMRN) offered a presentation that included important and new information regarding its R&D pipeline for 2019, observes biotech specialist John McCamant, editor of Medical Technology Stock Letter.

At the recent JPMorgan conference, ACADIA Pharmaceuticals (ACAD) presented a business update highlighting several catalysts anticipated in 2020, notes John McCamant, biotech sector expert and editor of Medical Technology Stock Letter.

Myovant Sciences Ltd. (MYOV) offers a new drug “pipeline in a pill”, asserts biotech expert Jay Silverman, contributing editor to Medical Technology Stock Letter.

On their recent conference call for The Medicines Company (MDCO), management highlighted the power of Inclisiran’s profile and likelihood of its potential to change the paradigm of ASCVD (atherosclerotic cardiovascular disease) treatment, notes biotech expert John McCamant, editor of The Medical Technology Stock Letter.

Market volatility has risen sharply as investors react to short-term geopolitical news. In the biotech sector, however, investment experts tend to remain focused on long-term developments such as clinical drug trials. For those with a long-term horizon, here are some favorites from MoneyShow.com contributors.

Last January, MoneyShow.com asked the leading newsletter advisors to select their favorite stocks for 2019. Healthcare was a popular sector in that survey, with several big first-half winners. Here’s a check-up on six healthcare favorites poised for the second half gains in 2019.

For investors interested in biotech, there’s a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times. John McCamant discusses Sangamo in this article.

In a rare move for a biotech expert who primarily takes bullish long-term positions, John McCamant has issued short sale recommendations for three stocks in the CRISPR space. The editor of The Medical Technology Stock Letter and contributor to MoneyShow.com explains his concerns about this specialized group while also reiterating a Strong Buy rating for one gene-editing play which does not rely on CRISPR technology.

One of the keys to long-term biotech investing is finding the big winners and riding them to huge gains, writes Medical Technology Stock Letter editor John McCamant and frequent MoneyShow.com contributor. Medical Technology Stock Letter has had many such winners over the years, including Genentech and Pharmacyclics. We provided multiple entry points to invest in Pharmacyclics starting at $17 and in three-plus years the company was sold to AbbVie for $262 per share or $21 billion. Over the last year and a quarter, our subscribers have been enjoying incredible gains with the Four Horsemen: Esperion Therapeutics. Madrigal Pharmaceuticals, Nektar Therapeutics, Sangamo Therapeutics.

As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.

Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.

Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.

Esperion (ESPR) hit a grand slam with triple therapy data, submitting an NDA filing and enrollment ahead of schedule, asserts biotech expert John McCamant, editor of The Medical Technology Stock Letter.

Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.

Non-alcoholic steatohepatitis, or NASH, is one of the largest disease opportunities we have ever seen, explains John McCamant, editor of The Medical technology Stock Letter.

The next-generation of cholesterol drugs were approved in 2016; these targeted drugs rapidly reduce LDL cholesterol in a wide variety of patients with cardiovascular disease, notes Jay Silverman, editor of the Medical Technology Stock Letter.

This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

John McCamant, editor The Medical Technology Stock Letter, reviews a favored biotech stock Incyte (INCY), noting that the company will have a very strong presence at the American Society of Hematology (ASH) Annual Meeting 2016 in early December.

The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.

This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.

John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he sees over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.

Four reasons for investors to buy biotechnology stocks now: Beaten-down biotechnology stocks have been so cheap for so long, rattled investors pray every day that a big drug company with firepower will swoop in and buy one to spark interest in the industry.

The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.

Dozens of biotech companies are ‘free’ for investors’ taking

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-Anthera Pharmaceuticals. #ANTH

John McCamant, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his biotech stock picks for 2015, one of which (FPRX) that has risen 50%. #FPRX #PCYC

Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his two biotech stock picks for 2015 that have risen 33% and 41%. #NVAX #MDCO

Recent volatility has created an environment for biotech stocks in which company fundamentals are mispriced relative to their stock prices, according to John McCamant. Here, the editor of The Medical Technology Stock Letter discusses the current state of the biotech market and highlights a trio of well-positioned stocks currently being undervalued by the market.

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

In January, MoneyShow asked all of the nation’s leading advisors to select a favorite stock for 2015. In this special series of interviews we are talking with the five advisors who had the top performing stock picks as of mid-year. Here, we talk with Jay Silverman, editor of The Medical Technology Stock Letter, to discuss a top performing biotechnology company.

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

Biotech buyout fever is going to continue. But be careful: You need to pick the right companies and hold them for years. Find out the reasons biotech buyouts will continue and stock picks from biotech analysts including John McCamant of BioInvest.

Gene Marcial of Forbes interviews John McCamant of the Medical Technology Stock Letter to discuss an attractive M&A play in the Biotech Space.

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Guest John McCamant, editor of the Medical Technology Stock Letter (MTSL), joins Wide World of Stocks host Damon Roberts to discuss a potential biotech bubble, merger mania, and opportunity with ZIOPHARM (NASDAQ: ZIOP)

Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.

John McCamant speaks with Damon Roberts, host of Wide World of Stocks “Sector Spotlight” about hot stock picks in the biotech sector. Wide World of Stocks (3-16-15)

Beware of biotech stocks. I’m not the only one who is skeptical of the latest monster move in biotech. “At current levels, we believe another pullback is due,” biotechnology expert John McCamant wrote in the most recent edition of his Medical Technology Stock Letter.

February 25, 2015 Is A Renaissance In Surging Biotechs Underway? By Gene Marciel Not too long ago, investing in biotechnology was perceived as plain gambling. The rewards could be high, to be sure, but so were the risks in playing the arcane biotech stocks. That was because a biotech company’s success depended on the development of[…]

February 25, 2015 Precision Medicine Boost Cancer Research By John McCamant John McCamant:  Sangamo (SGMO) is clearly a second generation gene therapy technology.  They can do a couple of different things than the first generation, but their technology is specifically it’s a rifled approach. They can get right into the specific point within the genome[…]

January 19, 2015 FIVE PRIME Written By John McCamant Our top speculative idea for 2015 a classic early-stage platform; the company is a leader in the discovery of innovative protein therapeutics, explains John McCamant, editor of The Medical Technology Stock Letter. Five Prime (FPRX) has built an extremely impressive library comprised of more than 5,600[…]

December 30, 2014 Will Biotech Fire on All Cylinders in 2015? Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before[…]

November 16, 2014 Weighing the Week Ahead: Time to Buy Commodities? …..Other Advice Here is our collection of great investor advice for this week: Stock ideas! The very hot biotech sector has pulled back a bit. (For traders, Felix actually has it as one of the few sectors that is not worth a “fresh money” buy[…]

November 6, 2014 Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound, but Investors Remain Enchanted by Big Pharma’s Solid Returns When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven’t yet entirely recouped[…]

November 3, 2014 Biotech Bets: Cardio, Cancer, Vaccines, and Ebola Jay Silverman is a biotechnology stock analyst and an editor at the industry leading biotech newsletter, The Medical Technology Stock Letter. Here, he offers an in-depth look at three of his favorite biotech stocks. Steven Halpern:  Our guest today is Jay Silverman, a biotech stock analyst with[…]

September 22, 2014 Five Prime: A Prime Play on Proteins By: John McCamant Following a recent meeting with top management at this firm, John McCamant—editor of The Medical Technology Stock Letter—has issued a buy recommendation for the early-stage biotech, noting that it could become a leader in immuno-oncology. Steven Halpern:  Our guest today is John McCamant, the[…]

September 3, 2014 ISIS Heart Drugs Get Good News Drugmaker’s News Encouraging Written By Bradley J. Fikes Strengthening the outlook for its drug development pipeline, Isis Pharmaceuticals has announced progress with two of its flagship cardiovascular drugs. On Tuesday, the Carlsbad biotech presented evidence that an already-approved drug, Kynamro, dramatically reduces risk of heart attacks.[…]

July 23, 2014 Mid-Year Top Picks for 2014 Written By Nancy Zambell Welcome to the Investment Digest Mid-Year Top Picks for 2014! This issue is our Mid-Year Top Picks Update. Many of our contributors’ recommendations returned double-digit gains so far this year. We’ve included sell recommendations on a few picks and six new Top Picks[…]

June 19, 2014 Fire Up the Immuno-Oncology Powerhouses: by : Editors, The Life Sciences Report Forecasting when we’ll have a cure for cancer remains beyond the predictive powers of researchers and investors. But forecasting the focus of the latest American Society of Clinical Oncology meeting was in the cards: Immuno-oncology took center stage. In this[…]

BioInvest News for NVAX – Novavax Enters Ebola Vaccine Race with a Bang – After remaining mum during the recent Ebola hype-fest, NVAX waited until they had truly legitimate news to report.  This weekend, the company released positive preclinical Ebola vaccine data in guinea pigs at the 8th Vaccine and ISV Conference in Philadelphia (10/26).[…]

March 12, 2014 Three Favorites from a Biotech Expert Biotechnology analyst Jay Silverman shares his outlook for the sector and the growing trend for large drug firms to acquire successful biotech firms. The editor of The Medical Technology Stock Letter also highlights a trio of current favorites in the sector., editor of . Steve Halpern:[…]

January 22, 2014 Top Picks for 2014 Written By Nancy Zambell Welcome to the Dick Davis Investment Digest  Top Picks for 2014. When we asked our contributors for their 2013 Top Picks, the Dow Jones Industrial Average had just closed out 2012 at 13,104.10. By the beginning of 2013, the DJIA was trading at 16,576.66—a[…]

January 15, 2014 The Life Sciences Report: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust by : Tracy Salcedo-Chourré 2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The[…]

January 6, 2014 Top Pros’ Top Picks Our top stock selection for 2014 has received three Breakthrough Therapy Designations (BTD) by the FDA, and subsequent approval, in November, for Imbruvica, a very safe pill that has shown unprecedented efficacy to treat mantle cell lymphoma (MCL), suggests John McCamant, editor of The Medical Technology Stock Letter.[…]

January 10, 2014 Top Pros’ Top Picks Stocks of biotechnology companies that reach major inflection points tend to outperform for several years. And our top speculative idea is a company that made a major leap forward in 2013, suggests Jay Silverman, editor of The Medical Technology Stock Letter. Novavax (NVAX) is executing its clinical plan[…]

January 3, 2014 Why Following the Winners Is for Losers by Mark Hulbert “Past performance is no guarantee of future results.” This phrase, ubiquitous in the small print of financial products, often falls on deaf ears, according to Adam Reed, a finance professor at the University of North Carolina at Chapel Hill. “Investors have a[…]

December 23, 2013 Profits in Pain Prevention The Medical Technology Stock Letter had one of the best performing stocks in this past year’s Top Picks special; here, Jay Silverman updates his view on this biotech winner and highlights some potential new leaders for the coming year. Steve Halpern: We’re here today with biotech expert Jay Silverman[…]

November 19, 2013 Novavax: Progress Against the Flu One of our core biotech holdings surprised us by publishing positive results in the most recent online edition of The New England Journal of Medicine (NEJM), notes John McCamant, editor of The Medical Technology Stock Letter. Novavax (NVAX) released its Phase I trial of 284 subjects injected[…]

November 11, 2013 Sector Pullback Makes Biotech a Buy by Steven Halpern for The Daily Guru Despite the fact that the biotech sector has faced some setbacks recently, Jay Silverman, editor of Medical Technology Stock Letter, is confident it’s only the case of a normal correction. Steve Halpern: We’re here today with biotech sector expert,[…]

September 26, 2013 The Life Sciences Report: John McCamant Scans Under the Radar for Promising Biotechs by : Peter Byrne The Life Sciences Report: The medical biotech sector has generally been going great guns in 2013. Is there a seasonal aspect to the overall performance of biotech stocks? Are some seasons preferable to other seasons[…]

Biotechs Are Back In Favor Amid Plethora Of Positive Developments Written By Gene Marcial, Contributor It isn’t often that the biotechnology industry gets swamped with plenty of good news, but that’s what has been happening in recent months. Not surprisingly, they have attracted investor interest. A number of new drug approvals, affirmative data, and accelerated[…]

September 23, 2013 Isis rises again on drug data by Bradley J. Fikes for The Union Tribune San Diego CARLSBAD — Shares of Isis Pharmaceuticals jumped up to 10 percent Monday after it reported more good clinical trial data for . Isis reached an intraday high of $39.83 before closing Monday at $38.48, up 6.7 percent[…]

September 19, 2013 Isis jumps on drug trial data by Bradley J. Fikes for The Union Tribune San Diego Isis Pharmaceuticals shares jumped 14 percent Thursday after the biotech company released positive preliminary Phase 1 results for its spinal muscular atrophy drug. Shares of Carlsbad-based Isis closed at $36.27, up $4.47 from Wednesday. The company’s market[…]

August 26, 2013 Biotechs Target Pain and Flu by Steven Halpern for The Daily Guru The Daily Guru Biotechs Target Pain and Flu. Jay Silverman, biotech analyst at The Medical Technology Stock Letter, looks at some favorite biotech stocks that are addressing potentially large, new markets. Steve Halpern: We’re here today with Jay Silverman of[…]

July 11, 2013 Best Bets in Biotech Written By Steven Halpern for The Daily Guru The Daily Guru Best Bets in Biotech. With the US facing an ageing population and Obamacare going online next year, biotech is about to enter its golden age, says John McCamant of Medical Technology Stock Letter. Steven Halpern: We’re here[…]

May 27, 2013 Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential Buyout Bet Written By Gene Marcial, Contributor Welcome to the super-sized Tiny Biotech Developing Drugs Akin To Biogen’s Rituxan Seen As Potential Buyout Bet. Unfortunately for investors in the arcane world of biotechnology, biotech stocks haven’t fully participated in the market’s[…]

May 9, 2013 The Life Sciences Report: Six Superstars for Your Biotech Portfolio by : Tracy Salcedo The Life Sciences Report: The consensus is that biotech is on the upswing and that it may be a safer bet for investors than gold or energy at this point in time. Do you agree? Can you tell[…]

January 31, 2013 The Life Sciences Report: Watchlist 2013 by George S. Mack Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their[…]

January 17, 2013 Top Picks for 2013 Written By John McCamant Pacira Pharmaceuticals (PCRX) is our top conservative stock recommendation for 2013. The specialty pharmaceutical company develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. The company’s drugs are based on its proprietary DepoFoam drug delivery technology. Its lead drug, Exparel, is a[…]

January 9, 2013 Top Picks for 2013 Written By Chloe Lutts Welcome to the super-sized Investment Digest Top Picks for 2013 issue. Inside this issue, you’ll find over 50 of our contributors’ very favorite investments to own this year. Plus, this year we’re bringing you an even wider selection of Top Picks through a collaboration with[…]

December 8, 2012 Don’t Be Surprised If Underpriced Small-Cap Biotechs Catch Investors’ Eye Once Again Written By Gene Marcial, Contributor Biotechnology stocks haven’t produced much excitement for investors this year, partly because the Presidential elections and national politics usurped much of the news headlines. So Wall Street and most investors have had little chance or inclination to focus[…]

John McCamant recommends in this year’s Top Stock picks from The Stock Advisors. Subscribers can read his full report on Pacira (see page 52) as well as learn more about all 70 stock recommendations in the PDF report below.  

November 27, 2012 Isis Pharmaceuticals: Antisense Value by John McCamant, editor The Medical Technology Stock Letter Isis Pharmaceuticals (ISIS) has had a lots of news. The first was the announcement that the company will receive $1.1 million from Alnylam as its portion of the upfront fees from a collaboration with Genzyme. The company also announced that[…]

October 25, 2012 John McCamant on Investing in Blood Cancer Written By George S. Max Hematological cancers present special opportunities for investors.  In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector.[…]

Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies TICKERS: AMGN, ASTX, CELG, CYCC, DNDN, PCYC, RHHBY October 25, 2012 Source: George S. Mack of The Life Sciences Report Hematological cancers present special opportunities for investors. In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology[…]

October 23, 2012 How to Find the Best Biotech Stocks Written By Chloe Lutts Have you ever wondered how to find great biotech stocks in a sea of hopeful but high-risk medical small caps? Well, for my latest Dick Davis Digest contributor interview, I interviewed John McCamant, the editor of a top-performing investment newsletter that’s all about[…]

October 4, 2012 Pick Biotech Winners Like A Pro: John McCamant Written By George S. Mack John McCamant, editor of the Medical Technology Stock Letter, doesn’t care if a scientist or a businessperson is at the helm of a biotech company, as long as management has skill and broad experience. Investors need to look for companies that[…]

September 6, 2012 Dizzying gains, stupefying losses in medical tech Commentary: A veteran newsletter repeats its ‘Matterhorn’ pattern Written By Peter Brimelow NEW YORK (MarketWatch) — Medical Technology Stock Letter continues to Matterhorn. What does that say about the market? The long established letter — editor John McCamant is the son of the founding editor,[…]